GlassScriptPhysician profile
David X Silkiner
NPI 1356382733
$1,385.82
in general payments reported to CMS, 2019-2025
25 companies · $280 in 2025
The $280 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $505 · 2020: $63.16 · 2022: $64.92 · 2023: $212 · 2024: $261 · 2025: $280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $753.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $752.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $206.44 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Abbvie INC. | $187.57 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Pfizer INC. | $170.28 | 2019-2025 | |
| Lilly USA, LLC | $105.95 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $81.56 | 2019-2024 | Veozah |
| Astrazeneca Pharmaceuticals LP | $69.32 | 2019 | |
| Dexcom, INC. | $58.98 | 2024-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $54.64 | 2019-2024 | Repatha, Otezla |
| Daiichi Sankyo INC. | $53.34 | 2019-2024 | Injectafer |
| Amarin Pharma, INC. | $49.57 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.47 | 2019-2024 | Tradjenta, Synjardy, Jardiance |
| Exact Sciences Corporation | $44.47 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novartis Pharmaceuticals Corporation | $35.76 | 2019-2023 | |
| Abbott Laboratories | $34.81 | 2019 | |
| Glaxosmithkline, LLC. | $23.10 | 2025 | Trelegy Ellipta |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $22.25 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $20.76 | 2022 | |
| Xeris Pharmaceuticals, INC. | $20.52 | 2024 | Gvoke Hypopen |
| Esperion Therapeutics, INC. | $16.63 | 2025 | Nexletol |
| Takeda Pharmaceuticals U.S.A., INC. | $16.54 | 2019 | |
| Phathom Pharmaceuticals, INC. | $13.88 | 2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $13.71 | 2022 | |
| Dynavax Technologies Corporation | $12.56 | 2024 | Heplisav-B |
| Shire North American Group INC | $12.23 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.48 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Silkiner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.